Clinical trials
catalyst calendar across sponsors →Studies where KRRO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 8 tracked-famous managers (Balyasny Asset Management L.P., AQR CAPITAL MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, +3 more) · FINRA short interest 9.2 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 15 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCDNCT07773246Safety and TolerabilityRandomized · Triple-masked · Treatment | Phase 1/2 | Not yet recruiting | Drug: KRRO-121, Placebo | Urea Cycle Disorders, Inborn, Urea Cycle Disorders, Ornithine Transcarbamylase (OTC) Deficiency, Arginase 1 Deficiency, NAGS Deficiency, Carbamylphosphate Synthetase I, Ornithine Transporter Mitochondrial 1, Argininosuccinate Synthase, Argininosuccinate Lyase Deficiency, N-acetyl Glutamate - Synthetase, Citrin Deficiency | 30 | Aug 2027 | ≤ 377 d | 2026-08-19 |
| A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110NCT06677307Safety and TolerabilityRandomized · Double-masked · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: The study was terminated for business decision reasons. | Drug: KRRO-110 | Alpha-1 Anti-trypsin Deficiency, AATD | 42 | 2025-10-31actual | — | 2026-04-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19